多発性硬化症における第一線疾患修正治療として,高効性対プラットフォーム療法を開始する予測要因
Khalid Bin Aziz1,2, Thamer S Alhowaish2,3, Feras Alanazi2,3
1College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
Frontiers in neurology
|February 16, 2026
まとめ
サウジアラビアでは,多発性硬化症 (MS) の第一線治療として,高効率性疾患修飾療法 (heDMT) がますます使用されています. 障害の結果は類似していたが,heDMTは治療の持続性と耐性を改善した.
科学分野:
- 神経学 神経学とは
- 免疫学 免疫学とは
- クリニック・セラピエティクス
背景:
- 多発性硬化症 (MS) の管理は,高効率性疾患修飾療法 (heDMT) の早期使用にシフトしています.
- 中東における第一線ヘディメット使用の予測要因と結果に関する現実世界のデータは限られている.
研究 の 目的:
- 再発性寛解性多発性硬化症 (RRMS) の第一線ヘッド・メディカル・セラピーとプラットフォーム・セラピーの選択に影響を与える要因を特定する.
- RRMS患者における障害のアウトカムと治療継続に対する初期治療クラスの影響を評価する.
主な方法:
- サウジアラビアの826人のRRMS患者 (2016年-2024年) の遡及コホート研究.
- heDMT開始予測器のための多変数ロジスティック回帰.
- 障害アウトカムのためのオーダーナルロジスティック回帰 (EDSS).
- 治療の持続と中止のための生存分析 (カプラン・マイヤー,コックス,ファイン・グレイ).
主要な成果:
- 40%の患者がファーストラインヘッドDMTを開始し,後の治療期および小脳発症の患者では使用が増加しました.
- ヘッド・DMTとプラットフォーム・セラピー・グループ間の障害レベルの有意な差はありません.
- heDMTの開始は,より優れた治療持続性と,より低い中止リスクと関連していました.
結論:
- サウジアラビアのファーストラインヘッドDMTの使用は,特に小脳発症の患者で増加しています.
- ヒートDMTの開始は,同様の障害の結果にもかかわらず,治療の持続性と耐受性において重要な利点を提供します.
- 発見は,早期の,集中的なMS管理を支持し,地域におけるヘッドDMTのより広範なアクセスと実施を提唱しています.
関連する概念動画
Factors Affecting Drug Response: Overview
3.1K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
3.1K
Psychosis: Goals of Pharmacotherapy
550
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
550
Drug Therapy
315
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
315
Therapeutic Drug Monitoring: Affecting Factors
256
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
256
Parkinson's Disease: Treatment
1.2K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
17
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
17


